Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isabgol (specifically the formulation marketed as Isabgul Plus by Ibn Sina Pharmaceutical Industry Ltd.) is a herbal combination product used for the management of various gastrointestinal conditions. It contains psyllium husk (*Plantago ovata*), which functions as a bulk-forming laxative by absorbing water to increase stool volume and facilitate transit, and senna leaf (*Cassia angustifolia*), a stimulant laxative that promotes bowel movement by acting on the enteric nervous system and inhibiting water absorption in the large intestine. The product is indicated for chronic constipation, irritable bowel syndrome (IBS), ulcerative colitis, and hemorrhoids. It is available as an effervescent powder or sachet for oral administration and is registered with the Directorate General of Drug Administration (DGDA) in Bangladesh.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on psyllium husk + senna leaf.